Overview
Effective pharmacovigilance and risk management practices are critical to ensuring that health products available to Canadians are safe and that risks associated with use are balanced with benefits in a way that best meets the needs of patients. Today’s safety and pharmacovigilance professionals must assess and manage risk for a broad range of new and traditional products, all within a changing landscape of global regulation.
DIA’s Canadian Pharmacovigilance and Risk Management Strategies Conference is the premier place to hear the latest updates in pharmacovigilance, risk management, and drug safety from both a global and a tailored Canadian perspective. In this year’s program, biopharmaceutical and regulatory agency experts will engage with the audience on topics such as Health Canada and global regulatory updates, impact of the pandemic crisis on pharmacovigilance, regulatory flexibility, signal detection, GVP inspections of foreign MAHs, and foreign notifications. A special look at vigilance for vaccines and COVID-19 therapies will also be featured.
Program Now Available!
The program has been released! Preview all session descriptions, speakers, and more all in one place!
ViewProgram Committee
-
Rita Cassola, RPh • Executive Director PV
Certus PV Services Inc, Canada -
Marcia Bailey, BSN, MHS, RN • Senior Manager, Pharmacovigilance
Sierra Oncology , Canada -
Marc Poitras, PhD, MBA • Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada, Canada -
Sophie Sommerer, MS • Director
Health Canada, Canada -
Bruce Valliant • Head of Pharmacovigilance and Medical Information
Pharmascience Inc., Canada
Contact us
Registration Questions?
Additional Information
Canadian Pharmacovigilance and Risk Management Conference Resource Kit
